What GSK's Q3 Results Mean For Theravance
Theravance ( THRX -1.8% ) and collaboration partner GlaxoSmithKline's ( GSK +1.7% ) Anoro Ellipta (umeclidinium/vilanterol) improved
By Early Retiree : Yesterday, Theravance (NASDAQ: THRX ) published a press release presenting positive results ..... lung function study comparing the efficacy and safety of Theravance 's Anoro Ellipta (umeclidinium/vilanterol), the
Theravance ( THRX -5.1% ) appoints Eric d'Esparbes as SVP and CFO. He joins the firm from Joule Unlimited where he had similar duties. Post your comment!
By Early Retiree : Introduction Theravance Biopharma (NASDAQ: TBPH ) was spun off Theravance (NASDAQ: THRX ) in June 2014 and basically is the old THRX minus the rights on three vilanterol-based products: Anoro
BABA ; sell puts as options on BABA start to trade on Monday; pg 20]; Apple [ AAPL ; pg 20]. Bearish stories: Theravance [ THRX ; pg 14]; agricultural sector [machinery AGCO, CNHI, DE ; fertilizer AGU, CF, MOS, POT ; seeds/chemicals
even become a SIFI ; its bank has had the top 5-yr CD rate for months ; pg 13]; Dow Chemical [ DOW ; pg 16]; Theravance [ THRX ; COPD drug royalty based company after the spinoff of R&D arm TBPH ; it sells COPD drugs through GSK ; pg 18
WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...
Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...
proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated